Insilico Medicine
Hong Kong, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A generative AI company pioneering target discovery and drug design to rapidly create novel therapeutics across multiple diseases.
OncologyFibrosisImmunology
Technology Platform
Pharma.AI platform, a generative AI suite for target discovery (PandaOmics), molecule generation (Chemistry42), and clinical trial prediction.
Opportunities
Expanding its internal pipeline into lucrative disease areas and securing more large-scale strategic partnerships with big pharma.
Risk Factors
The unproven long-term clinical success rate of AI-discovered drugs and high valuation sensitivity to clinical data readouts.
Competitive Landscape
A top contender in the AI drug discovery space, competing on the breadth and clinical validation of its generative AI platform against peers like Exscientia.